Business Wire

 Panasonic and KOSÉ Set to Commence Verification Test for Personalized Proposals Utilizing Snow Beauty Mirror

6.12.2019 05:37:00 EET | Business Wire | Press release

Share

Panasonic Corporation is collaborating with KOSÉ Corporation to conduct a joint verification test using Snow Beauty Mirror, a system under development by Panasonic, with the aim of offering personalized proposals at Maison KOSÉ, a store which is due to open on December 17. Through this initiative, Panasonic will help make new personalized proposals that meet the diverse needs of its customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005971/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Snow Beauty Mirror (Displays the results of skin analysis covering five categories) (Photo: Business Wire)

People’s values and lifestyles are becoming increasingly diverse. In today’s world, everyone requires something different from their cosmetics. Meanwhile, customers are confronted with a deluge of information through the Internet and social media, which sometimes makes it difficult for them to select cosmetics that really suit their needs. A solution to this conundrum is personalized proposals which utilize digital technologies and data to introduce individuals to the optimal products and services.

Maison KOSÉ is a new type of concept store, a place where people will be able to come and experience these personalized proposals firsthand using Snow Beauty Mirror. Visitors will also be able to try out Customized Sheets (provisional name), which adopts the Make-up Sheet technology currently under development at Panasonic.

Functions of Snow Beauty Mirror and content of verification test

1. Skin analysis

All customers need to do is sit in front of the mirror. The system then analyzes the customer’s skin profile and displays numerical data instantly on the mirror. Contactless sensors embedded in the mirror detect the condition of both the skin’s surface and below the surface. With a degree of precision on par with medical devices, the system detects not only spots, wrinkles, smile lines, pores and skin tone, but also hidden spots otherwise invisible to the naked eye. Then, based on digital counselling and analysis results, the system recommends the optimal package for each individual customer from among KOSÉ’s products and services spanning multiple brands*1. This function utilizes facial recognition and image processing technologies used in digital cameras, et al.

2. Ideal face image system

Combining genetic algorithms, developed as a joint venture between KOSÉ and Meiji University, with Panasonic’s image processing technologies has enabled the creation of a system which makes it possible to visualize a person’s “ideal face” from facial image data—that is, how the customer would really like to appear. Snow Beauty Mirror’s high-precision skin analysis function detects the customer’s skin conditions in terms of pores, spots and wrinkles, as well as the skin’s tones and brightness, and adjusts the parameters of this data to create around 500,000 facial image patterns. The customer selects their preferred facial image from among randomly displayed facial images, generating their ideal face in a short time. The system can visualize the differences between the customer’s ideal face and current appearance, while providing tips on the perfect foundation tone, texture and application techniques to help them get closer to their ideal face.

3. Customized Sheets which apply Make-up Sheet technology

Currently under development at Panasonic, Make-up Sheets are ultra-thin*2 cosmetic sheets printed with tones that perfectly match the customer’s skin. They combine skin analysis data from Snow Beauty Mirror, and the company’s proprietary printing technology. Customers simply need to stick the sheets over areas of concern on their cheeks or temples.

In this verification test, Panasonic will combine its Make-up Sheet technology, proprietary skin tone analysis technology, and printing technology with KOSÉ’s extensive knowledge of cosmetic development. The aim is to create Customized Sheets (provisional name) that achieve a natural color match and an ideal fit with the customer’s skin.


Panasonic will continue to fuse its cutting-edge technologies with KOSÉ’s development capabilities in cosmetics to expand the scope of Snow Beauty Mirror, pursuing possibilities that go beyond the field of beauty treatment. In this way, the company will meet the diverse needs of its customers and better contribute to society through improved QOL.

Notes:
*1. KOSÉ Group’s skin care brands, excluding ALBION
*2. Thickness of 100 nanometers (one nanometer = one billionth of a meter)

About Maison KOSÉ

A fun concept store stocking and linking all KOSÉ brands*3, providing customers with an early chance to try a range of new software and hardware relating to cosmetics and beauty treatment. The store facilitates new forms of communication which fuse digital and experiential approaches, exploring new possibilities for the next generation of cosmetic experiences and working to connect customers digitally to the store. It also serves as a place of communication with customers, functioning as a seat of learning where information and experiences can be quickly fed back into the company.

*3 Excluding some products

About Panasonic

Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.

Source: https://news.panasonic.com/global/press/data/2019/12/en191206-2/en191206-2.html

Related Links

[Video] Make-up Sheet / Technology & Innovation of Panasonic
https://channel.panasonic.com/contents/25818/

[Video] Solving skin concerns with innovation using the “Make-up Sheet” [Panasonic]
https://channel.panasonic.com/contents/25819/

Brand Story | Panasonic
https://www.panasonic.com/global/corporate/brand/story.html

Panasonic R&D Overview | Panasonic
https://www.panasonic.com/global/corporate/technology-design/r-and-d.html

Breakthrough Technology | Panasonic
https://www.panasonic.com/global/corporate/technology-design/technology.html

KOSÉ Corporation
https://www.kose.co.jp/global/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Panasonic
Innovation Strategy Office
Technology Public Relations Section
crdpress@ml.jp.panasonic.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye